Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 2, 2014, Pages 330-341

  Kruger, Thomas E ^a   Miller, Andrew H ^a   Godwin, Andrew K ^a,b   Wang, Jinxi ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

Bone metastasis; Bone sialoprotein; Malignancy; Osteopontin

Indexed keywords

BONE SIALOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; NUCLEAR FACTOR INDUCING KINASE; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PROTEIN ANTIBODY; PROTEIN KINASE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; BONE CANCER; BONE METABOLISM; BONE METASTASIS; CANCER CELL; CANCER PROGNOSIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE ASSOCIATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; MOLECULARLY TARGETED THERAPY; OSTEOTROPIC CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT;

BONE METASTASIS; BONE SIALOPROTEIN; MALIGNANCY; OSTEOPONTIN;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN-BINDING SIALOPROTEIN; NEOPLASM METASTASIS; OSTEOPONTIN;

EID: 84892496703     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.08.013     Document Type: Review

References (141)

1. American Cancer Society: Cancer Facts and Figures 2008, Available from: www.cancer.org.
2. Coleman R.E. Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
3. Brown J.E., Sim S. Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia 2010, 12:685-696.
4. Guise T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12. p. 6213 s-6216s.
5. Fisher L.W., Fedarko N.S. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 2003, 44(Suppl 1):33-40.
6. Bellahcene A., Castronovo V. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. Bull Cancer 1997, 84:17-24.
7. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295(5564):2387-2392.
8. Bellahcene A., Castronovo V., Ogbureke K.U., Fisher L.W., Fedarko N.S. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008, 8:212-226.
9. Fisher L.W., McBride O.W., Termine J.D., Young M.F. Human bone sialoprotein. Deduced protein sequence and chromosomal localization. J Biol Chem 1990, 265:2347-2351.
10. Masi L., Brandi M.L., Robey P.G., Crescioli C., Calvo J.C., Bernabei P., et al. Biosynthesis of bone sialoprotein by a human osteoclast-like cell line (FLG 29.1). J Bone Miner Res 1995, 10:187-196.
11. Chen J., Shapiro H.S., Sodek J. Development expression of bone sialoprotein mRNA in rat mineralized connective tissues. J Bone Miner Res 1992, 7:987-997.
12. Kasugai S., Nagata T., Sodek J. Temporal studies on the tissue compartmentalization of bone sialoprotein (BSP): osteopontin (OPN), and SPARC protein during bone formation in vitro. J Cell Physiol 1992, 152:467-477.
13. Sodek J., Overall C.M. Matrix metalloproteinases in periodontal tissue remodelling. Matrix Suppl 1992, 1:352-362.
14. Fisher L.W., Torchia D.A., Fohr B., Young M.F., Fedarko N.S. Flexible structures of SIBLING proteins: bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001, 280:460-465.
15. Xu L., Anderson A.L., Lu Q., Wang J. Role of fibrillar structure of collagenous carrier in bone sialoprotein-mediated matrix mineralization and osteoblast differentiation. Biomaterials 2007, 28:750-761.
16. Valverde P., Tu Q., Chen J. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. J Bone Miner Res 2005, 20:1669-1679.
17. Bellahcene A., Bonjean K., Fohr B., Fedarko N.S., Robey F.A., Young M.F., et al. Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ Res 2000, 86:885-891.
18. Chen J., Rodriguez J.A., Barnett B., Hashimoto N., Tang J., Yoneda T. Bone sialoprotein promotes tumor cell migration in both in vitro and in vivo models. Connect Tissue Res 2003, 44(Suppl 1):279-284.
19. Fedarko N.S., Fohr B., Robey P.G., Young M.F., Fisher L.W. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 2000, 275:16666-16672.
20. Bellahcene A., Merville M.P., Castronovo V. Expression of bone sialoprotein: a bone matrix protein, in human breast cancer. Cancer Res 1994, 54:2823-2826.
21. Waltregny D., Bellahcene A., Van Riet I., Fisher L.W., Young M., Fernandez P., et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998, 90:1000-1008.
22. Bellahcene A., Maloujahmoum N., Fisher L.W., Pastorino H., Tagliabue E., Menard S., et al. Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 1997, 61:183-188.
23. Bellahcene A., Albert V., Pollina L., Basolo F., Fisher L.W., Castronovo V. Ectopic expression of bone sialoprotein in human thyroid cancer. Thyroid 1998, 8:637-641.
24. Detry C., Waltregny D., Quatresooz P., Chaplet M., Kedzia W., Castronovo V., et al. Detection of bone sialoprotein in human (pre)neoplastic lesions of the uterine cervix. Calcif Tissue Int 2003, 73:9-14.
25. Bellahcene A., Van Riet I., de Greef C., Antoine N., Young M.F., Van Camp B., et al. Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients. Br J Haematol 2000, 111:1118-1121.
26. Barnes G.L., Javed A., Waller S.M., Kamal M.H., Hebert K.E., Hassan M.Q., et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003, 63:2631-2637.
27. Pratap J., Lian J.B., Stein G.S. Metastatic bone disease: role of transcription factors and future targets. Bone 2011, 48:30-36.
28. Li Z., Wang Z., Yang L., Li X., Sasaki Y., Wang S., et al. Fibroblast growth factor 2 regulates bone sialoprotein gene transcription in human breast cancer cells. J Oral Sci 2010, 52:125-132.
29. Li Z., Sasaki Y., Mezawa M., Wang S., Li X., Yang L., et al. cAMP and fibroblast growth factor 2 regulate bone sialoprotein gene expression in human prostate cancer cells. Gene 2011, 471:1-12.
30. Pecheur I., Peyruchaud O., Serre C.M., Guglielmi J., Voland C., Bourre F., et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002, 16:1266-1268.
31. Sung V., Stubbs J.T., Fisher L., Aaron A.D., Thompson E.W. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 1998, 176:482-494.
32. Gordon J.A., Sodek J., Hunter G.K., Goldberg H.A. Bone sialoprotein stimulates focal adhesion-related signaling pathways: role in migration and survival of breast and prostate cancer cells. J Cell Biochem 2009, 107:1118-1128.
33. Sharp J.A., Waltham M., Williams E.D., Henderson M.A., Thompson E.W. Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin Exp Metastasis 2004, 21:19-29.
34. Fedarko N.S., Jain A., Karadag A., Fisher L.W. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J 2004, 18:734-736.
35. Karadag A., Ogbureke K.U., Fedarko N.S., Fisher L.W. Bone sialoprotein: matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 2004, 96:956-965.
36. Zhang J.H., Tang J., Wang J., Ma W., Zheng W., Yoneda T., et al. Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol 2003, 23:1043-1048.
37. Nam J.S., Suchar A.M., Kang M.J., Stuelten C.H., Tang B., Michalowska A.M., et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 2006, 66:6327-6335.
38. Zhang J.H., Wang J., Tang J., Barnett B., Dickson J., Hahsimoto N., et al. Bone sialoprotein promotes bone metastasis of a non-bone-seeking clone of human breast cancer cells. Anticancer Res 2004, 24:1361-1368.
39. Tu Q., Zhang J., Fix A., Brewer E., Li Y.P., Zhang Z.Y., et al. Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells. J Cell Physiol 2009, 218:135-145.
40. Reinholt F.P., Hultenby K., Oldberg A., Heinegard D. Osteopontin - a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A 1990, 87:4473-4475.
41. Wang K.X., Denhardt D.T. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008, 19:333-345.
42. Nagasaka A., Matsue H., Matsushima H., Aoki R., Nakamura Y., Kambe N., et al. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur J Immunol 2008, 38:489-499.
43. Burdo T.H., Wood M.R., Fox H.S. Osteopontin prevents monocyte recirculation and apoptosis. J Leukoc Biol 2007, 81:1504-1511.
44. Crawford H.C., Matrisian L.M., Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998, 58:5206-5215.
45. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001, 107:1055-1061.
46. Standal T., Borset M., Sundan A. Role of osteopontin in adhesion: migration, cell survival and bone remodeling. Exp Oncol 2004, 26:179-184.
47. Ashizawa N., Graf K., Do Y.S., Nunohiro T., Giachelli C.M., Meehan W.P., et al. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest 1996, 98:2218-2227.
48. Murry C.E., Giachelli C.M., Schwartz S.M., Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 1994, 145:1450-1462.
49. Ikeda T., Shirasawa T., Esaki Y., Yoshiki S., Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993, 92:2814-2820.
50. Uaesoontrachoon K., Yoo H.J., Tudor E.M., Pike R.N., Mackie E.J., Pagel C.N. Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. Int J Biochem Cell Biol 2008, 40:2303-2314.
51. Kunii Y., Niwa S., Hagiwara Y., Maeda M., Seitoh T., Suzuki T. The immunohistochemical expression profile of osteopontin in normal human tissues using two site-specific antibodies reveals a wide distribution of positive cells and extensive expression in the central and peripheral nervous systems. Med Mol Morphol 2009, 42:155-161.
52. Rangaswami H., Bulbule A., Kundu G.C. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006, 16:79-87.
53. Wai P.Y., Kuo P.C. The role of osteopontin in tumor metastasis. J Surg Res 2004, 121:228-241.
54. Wai P.Y., Kuo P.C. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008, 27:103-118.
55. Furger K.A., Allan A.L., Wilson S.M., Hota C., Vantyghem S.A., Postenka C.O., et al. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 2003, 1:810-819.
56. Rice J., Courter D.L., Giachelli C.M., Scatena M. Molecular mediators of alphavbeta3-induced endothelial cell survival. J Vasc Res 2006, 43:422-436.
57. Kawamura K., Iyonaga K., Ichiyasu H., Nagano J., Suga M., Sasaki Y. Differentiation: maturation, and survival of dendritic cells by osteopontin regulation. Clin Diagn Lab Immunol 2005, 12:206-212.
58. Iczkiewicz J., Jackson M.J., Smith L.A., Rose S., Jenner P. Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Res 2006, 1118:239-250.
59. Hur E.M., Youssef S., Haws M.E., Zhang S.Y., Sobel R.A., Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007, 8:74-83.
60. Christensen B., Kazanecki C.C., Petersen T.E., Rittling S.R., Denhardt D.T., Sorensen E.S. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem 2007, 282(27):19463-19472.
61. Lee J.L., Wang M.J., Sudhir P.R., Chen G.D., Chi C.W., Chen J.Y. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 2007, 67:2089-2097.
62. Khan S.A., Cook A.C., Kappil M., Gunthert U., Chambers A.F., Tuck A.B., et al. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 2005, 22:663-673.
63. Hayashi C., Rittling S., Hayata T., Amagasa T., Denhardt D., Ezura Y., et al. Serum osteopontin: an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. J Cell Biochem 2007, 101:979-986.
64. Caers J., Gunthert U., De Raeve H., Van Valckenborgh E., Menu E., Van Riet I., et al. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5 T33 MM model. Br J Haematol 2006, 132:469-477.
65. Khodavirdi A.C., Song Z., Yang S., Zhong C., Wang S., Wu H., et al. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 2006, 66:883-888.
66. Tuck A.B., Arsenault D.M., O'Malley F.P., Hota C., Ling M.C., Wilson S.M., et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999, 18:4237-4246.
67. Mi Z., Guo H., Wai P.Y., Gao C., Kuo P.C. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 2006, 27:1134-1145.
68. Kolb A., Kleeff J., Guweidhi A., Esposito I., Giese N.A., Adwan H., et al. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther 2005, 4:740-746.
69. Hu Z., Lin D., Yuan J., Xiao T., Zhang H., Sun W., et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005, 11:4646-4652.
70. Oates A.J., Barraclough R., Rudland P.S. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996, 13:97-104.
71. Thalmann G.N., Sikes R.A., Devoll R.E., Kiefer J.A., Markwalder R., Klima I., et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999, 5:2271-2277.
72. Agrawal D., Chen T., Irby R., Quackenbush J., Chambers A.F., Szabo M., et al. Osteopontin identified as lead marker of colon cancer progression: using pooled sample expression profiling. J Natl Cancer Inst 2002, 94:513-521.
73. Rittling S.R., Chambers A.F. Role of osteopontin in tumour progression. Br J Cancer 2004, 90:1877-1881.
74. Huan J.L., Xing L., Qin X.J., Gao Z.G., Pan X.F., Zhao Z.D. Expression and clinical significance of osteopontin in calcified breast tissue. Asian Pac J Cancer Prev 2012, 13:5219-5223.
75. Agnihotri R., Crawford H.C., Haro H., Matrisian L.M., Havrda M.C., Liaw L. Osteopontin: a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001, 276:28261-28267.
76. Dean R.A., Overall C.M. Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics 2007, 6:611-623.
77. Takafuji V., Forgues M., Unsworth E., Goldsmith P., Wang X.W. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 2007, 26:6361-6371.
78. Teramoto H., Castellone M.D., Malek R.L., Letwin N., Frank B., Gutkind J.S., et al. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene 2005, 24:489-501.
79. Schulze E.B., Hedley B.D., Goodale D., Postenka C.O., Al-Katib W., Tuck A.B., et al. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat 2008, 112:243-254.
80. Young M.F., Kerr J.M., Termine J.D., Wewer U.M., Wang M.G., McBride O.W., et al. cDNA cloning: mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 1990, 7:491-502.
81. Kiefer M.C., Bauer D.M., Barr P.J. The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Res 1989, 17:3306.
82. Crosby A.H., Edwards S.J., Murray J.C., Dixon M.J. Genomic organization of the human osteopontin gene: exclusion of the locus from a causative role in the pathogenesis of dentinogenesis imperfecta type II. Genomics 1995, 27:155-160.
83. Christensen B., Nielsen M.S., Haselmann K.F., Petersen T.E., Sorensen E.S. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 2005, 390:285-292.
84. Sorensen E.S., Rasmussen L.K., Moller L., Jensen P.H., Hojrup P., Petersen T.E. Localization of transglutaminase-reactive glutamine residues in bovine osteopontin. Biochem J 1994, 304(Pt 1):13-16.
85. Higashikawa F., Eboshida A., Yokosaki Y. Enhanced biological activity of polymeric osteopontin. FEBS Lett 2007, 581:2697-2701.
86. Anborgh P.H., Mutrie J.C., Tuck A.B., Chambers A.F. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal 2011, 5:111-122.
87. He B., Mirza M., Weber G.F. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006, 25:2192-2202.
88. Mirza M., Shaughnessy E., Hurley J.K., Vanpatten K.A., Pestano G.A., He B., et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008, 122:889-897.
89. Patani N., Jouhra F., Jiang W., Mokbel K. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 2008, 28:4105-4110.
90. Allan A.L., George R., Vantyghem S.A., Lee M.W., Hodgson N.C., Engel C.J., et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 2006, 169:233-246.
91. Cook A.C., Tuck A.B., McCarthy S., Turner J.G., Irby R.B., Bloom G.C., et al. Osteopontin induces multiple changes in gene expression that reflect the six hallmarks of cancer in a model of breast cancer progression. Mol Carcinog 2005, 43:225-236.
92. Goparaju C.M., Pass H.I., Blasberg J.D., Hirsch N., Donington J.S. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol 2010, 5:1516-1523.
93. Blasberg J.D., Goparaju C.M., Pass H.I., Donington J.S. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg 2010, 139:1587-1593.
94. Tilli T.M., Thuler L.C., Matos A.R., Coutinho-Camillo C.M., Soares F.A., da Silva E.A., et al. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol 2012, 92:13-19.
95. Tilli T.M., Mello K.D., Ferreira L.B., Matos A.R., Accioly M.T., Faria P.A., et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 2012, 72:1688-1699.
96. Tuck A.B., Hota C., Wilson S.M., Chambers A.F. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 2003, 22:1198-1205.
97. Xuan J.W., Hota C., Chambers A.F. Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem 1994, 54:247-255.
98. Ek-Rylander B., Flores M., Wendel M., Heinegard D., Andersson G. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J Biol Chem 1994, 269(21):14853-14856.
99. Ek-Rylander B., Andersson G. Osteoclast migration on phosphorylated osteopontin is regulated by endogenous tartrate-resistant acid phosphatase. Exp Cell Res 2010, 316:443-451.
100. Julien S., Picco G., Sewell R., Vercoutter-Edouart A.S., Tarp M., Miles D., et al. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer 2009, 100:1746-1754.
101. Cazet A., Julien S., Bobowski M., Burchell J., Delannoy P. Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res 2010, 12:204.
102. Clark E.A., Brugge J.S. Integrins and signal transduction pathways: the road taken. Science 1995, 268:233-239.
103. Hood J.D., Cheresh D.A. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002, 2:91-100.
104. Alper O., Bowden E.T. Novel insights into c-Src. Curr Pharm Des 2005, 11:1119-1130.
105. Volberg T., Romer L., Zamir E., Geiger B. pp60(c-src) and related tyrosine kinases: a role in the assembly and reorganization of matrix adhesions. J Cell Sci 2001, 114:2279-2289.
106. Das R., Mahabeleshwar G.H., Kundu G.C. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 2004, 279:11051-11064.
107. Lin Y.H., Yang-Yen H.F. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 2001, 276:46024-46030.
108. Wang H.S., Hung Y., Su C.H., Peng S.T., Guo Y.J., Lai M.C., et al. CD44 cross-linking induces integrin-mediated adhesion and transendothelial migration in breast cancer cell line by up-regulation of LFA-1 (alpha L beta2) and VLA-4 (alpha4beta1). Exp Cell Res 2005, 304:116-126.
109. Bellahcene A., Menard S., Bufalino R., Moreau L., Castronovo V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 1996, 69:350-353.
110. Gillespie M.T., Thomas R.J., Pu Z.Y., Zhou H., Martin T.J., Findlay D.M. Calcitonin receptors: bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 1997, 73:812-815.
111. Ibrahim T., Leong I., Sanchez-Sweatman O., Khokha R., Sodek J., Tenenbaum H.C., et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 2000, 18:253-260.
112. Papotti M., Kalebic T., Volante M., Chiusa L., Bacillo E., Cappia S., et al. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol 2006, 24:4818-4824.
113. Zhang L., Hou X., Lu S., Rao H., Hou J., Luo R., et al. Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study. Lung Cancer 2010, 67:114-119.
114. Bellahcene A., Kroll M., Liebens F., Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 1996, 11:665-670.
115. Diel I.J., Solomayer E.F., Seibel M.J., Pfeilschifter J., Maisenbacher H., Gollan C., et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 1999, 5:3914-3919.
116. Loibl S., Konigs A., Kaufmann M., Costa S.D., Bischoff J. PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients. Zentralbl Gynakol 2006, 128:330-335.
117. Withold W., Armbruster F.P., Karmatschek M., Reinauer H. Bone sialoprotein in serum of patients with malignant bone diseases. Clin Chem 1997, 43:85-91.
118. Seibel M.J., Woitge H.W., Pecherstorfer M., Karmatschek M., Horn E., Ludwig H., et al. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 1996, 81:3289-3294.
119. Woitge H.W., Pecherstorfer M., Horn E., Keck A.V., Diel I.J., Bayer P., et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 2001, 84:344-351.
120. He J.J., Zhi K., Liu G.F. Predictive value of serum bone sialoprotein in patients with bone metastasis of non-small cell lung cancer. Onkologie 2011, 34:584-588.
121. Uccello M., Malaguarnera G., Vacante M., Motta M. Serum bone sialoprotein levels and bone metastases. J Cancer Res Ther 2011, 7:115-119.
122. Fedarko N.S., Jain A., Karadag A., Van Eman M.R., Fisher L.W. Elevated serum bone sialoprotein and osteopontin in colon: breast, prostate, and lung cancer. Clin Cancer Res 2001, 7:4060-4066.
123. Jain A., McKnight D.A., Fisher L.W., Humphreys E.B., Mangold L.A., Partin A.W., et al. Small integrin-binding proteins as serum markers for prostate cancer detection. Clin Cancer Res 2009, 15:5199-5207.
124. Bramwell V.H., Doig G.S., Tuck A.B., Wilson S.M., Tonkin K.S., Tomiak A., et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006, 12:3337-3343.
125. Ye Q.H., Qin L.X., Forgues M., He P., Kim J.W., Peng A.C., et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003, 9:416-423.
126. Bauerle T., Adwan H., Kiessling F., Hilbig H., Armbruster F.P., Berger M.R. Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 2005, 115(2):177-186.
127. Bauerle T., Peterschmitt J., Hilbig H., Kiessling F., Armbruster F.P., Berger M.R. Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein. Int J Oncol 2006, 28:573-583.
128. Wang L., Wang J., Yang D., Yang C., Xia B., Xian J. Inhibitory effect of bone sialoprotein silencing on the adhesion ability of breast cancer cells to bone matrix. Sheng Wu Gong Cheng Xue Bao 2011, 27:233-239.
129. Zepp M., Armbruster F.P., Berger M.R. Rat monoclonal antibodies against bone sialoprotein II inhibit tumor growth and osteolytic lesions in nude rats induced by MDA-MB-231 breast cancer cells. Int J Clin Pharmacol Ther 2010, 48:462-464.
130. Wai P.Y., Mi Z., Guo H., Sarraf-Yazdi S., Gao C., Wei J., et al. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 2005, 26:741-751.
131. Zhang A., Liu Y., Shen Y., Xu Y., Li X. Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells. Med Oncol 2010, 27:1179-1184.
132. Reufsteck C., Lifshitz-Shovali R., Zepp M., Bauerle T., Kubler D., Golomb G., et al. Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions. Clin Exp Metastasis 2012, 29:441-456.
133. Adwan H., Bauerle T.J., Berger M.R. Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther 2004, 11:109-120.
134. Ito T., Hashimoto Y., Tanaka E., Kan T., Tsunoda S., Sato F., et al. An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2006, 12:1308-1316.
135. Guise T.A., Yin J.J., Taylor S.D., Kumagai Y., Dallas M., Boyce B.F., et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996, 98:1544-1549.
136. Campbell J.P., Karolak M.R., Ma Y., Perrien D.S., Masood-Campbell S.K., Penner N.L., et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol 2012, 10:e1001363.
137. Yoneda T., Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005, 328:679-687.
138. Sterling J.A., Edwards J.R., Martin T.J., Mundy G.R. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011, 48:6-15.
139. Theriault R.L. Biology of bone metastases. Cancer Control 2012, 19:92-101.
140. Koeneman K.S., Yeung F., Chung L.W. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999, 39:246-261.
141. Bellahcene A., Bachelier R., Detry C., Lidereau R., Clezardin P., Castronovo V. Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 2007, 101:135-148.